Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James George

Gastroenterology New York, NY Medical Doctor

NPI 1659380244 CMS profile 75351

1751 York Ave, New York, NY 10128

Open in the dashboard

General payments

$375,751

2,104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$64,895

4 holdings reported · through program year 2025

Through program year 2025, James George of New York, NY is reported in the CMS Open Payments database as having received $375,751 across 2,104 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $64,895 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $139,776 423
2024 General $53,496 332
2023 General $32,130 302
2022 General $33,890 332
2021 General $29,899 247
2020 General $15,019 186
2019 General $71,542 282
2022 Ownership $11,422 1
2021 Ownership $19,028 1
2020 Ownership $18,333 1
2019 Ownership $16,111 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James George
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to James George were reported at $139,776. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year James George Gastroenterology median Middle half National median
2019 $71,542 $417 $126–$1,100 $163
2020 $15,019 $224 $74–$624 $114
2021 $29,899 $352 $106–$1,054 $132
2022 $33,890 $448 $129–$1,270 $149
2023 $32,130 $533 $150–$1,390 $160
2024 $53,496 $605 $160–$1,606 $164
2025 $139,776 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $145,884 275 payments
  2. Janssen Scientific Affairs, LLC $88,657 88 payments
  3. AbbVie, Inc. $86,860 436 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $37,499 205 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,080 229 payments
  6. Celgene Corporation $3,021 291 payments
  7. Pfizer Inc. $2,793 148 payments
  8. Merck Sharp & Dohme Corporation $895 46 payments
  9. QOL Medical, LLC $875 35 payments
  10. Ferring Pharmaceuticals Inc. $712 63 payments
  11. Other $5,476 288 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $285,531 114 payments
  2. Food and Beverage $42,331 1,914 payments
  3. Travel and Lodging $37,708 65 payments
  4. Consulting Fee $9,975 6 payments
  5. Education $183 4 payments
  6. Long term medical supply or device loan $24 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $129,286 223 payments
  2. TREMFYA $128,256 157 payments
  3. RINVOQ $44,338 182 payments
  4. SKYRIZI Immunology $24,942 128 payments
  5. ENTYVIO Internal Medicine $20,130 161 payments
  6. Entyvio Lower GI $14,466 21 payments
  7. SKYRIZI Immunology $13,255 95 payments
  8. ZEPOSIA $3,021 291 payments
  9. XIFAXAN $2,548 194 payments
  10. XELJANZ $2,133 109 payments
  11. Other $14,378 786 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

2,104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record